**MINUTES**

**CPIC CONFERENCE CALL**

DATE: August 2, 2018

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress  | Guideline updates in progress:* *TPMT/NUDT15/*thiopurines*-* In review with CPT
* *CYP2C9/HLA/*phenytoin: In author evidence review

New guidelines in progress: * *RYR1*/inhaled anesthetics: In review with CPT
* *CYP2B6*/efavirenz: Drafting guideline
* *CYP2D6/*atomoxetine: Drafting guideline
* *CYP2C19/*PPI: Evidence review underway
* *CYP2C9/*celecoxib: Evidence review underway
 | Guideline preparation will continue and Kelly will continue to follow-up. |
| Nomination of *CYP2D6*/codeine for update  | Kelly discussed the need to update the *CYP2D6*/codeine guideline. The FDA has added a new contraindication recommending against the use of codeine in children less than 18. Also, since we have updated our SOP to include an additional recommendation scoring group (“no recommendation”) and changed our definition of optional to include weak evidence, we need to reevaluate other opioids (such as hydrocodone, oxycodone, tramadol, etc) and provide a formal recommendation. Members recommended for authors to consider also evaluating any evidence for CYP3A and fentanyl and oxycodone.  | If you are interested in being considered for authorship of this guideline update, please email Kelly Caudle (Kelly.caudle@stjude.org). |
| Nomination of MtRNR1/aminoglycosides to guideline list | Guidelines in progress and guideline prioritization criteria can be found here: <https://cpicpgx.org/prioritization-of-cpic-guidelines/>. Kelly nominated the addition of *MtRNR1*/aminoglycosides to this list. Prioritization on initiating the guideline process for this guideline will be decided based input from CPIC members and the CPIC guidelines prioritization criteria.  | Kelly will continue to follow-up. |
| Update on gudelines.gov | Funding to support AHRQ's National Guideline Clearinghouse (NGC) ended on July 16, 2018 (https://www.ahrq.gov/gam/updates/index.html). The best way to access CPIC guidelines and updates to CPIC guidelines is the CPIC guidelines pages (https://cpicpgx.org/guidelines/). | Kelly will continue to update CPIC members.  |
| ASCO endorsement of CPIC guidelines follow-up | ASCO has a formal process for endorsing clinical practice guidelines (attached with minutes). We will be submitting four guidelines for consideration (*TPMT-NUDT15*-thiopurines, *DPYD*/5-FU, *CYP2D6*/tamoxifen, *CYP2D6*/ondansetron, tropisetron) and submit others when/if warranted.  | Kelly will continue to update CPIC members. |